Novartis's defining moves.
The defining strategic moves at Novartis — each one explained and grounded in the record.
The Cannibalization Choice · Cannibalization Choice
Novartis Spent a Decade Selling Off Its Own Insurance Policy. The Bet Is Now Naked.
Over ten years Novartis shed Alcon, vaccines, consumer health, and finally Sandoz - trading revenue diversity for a pure-play bet. In 2024 it paid off: $50.3 billion in revenue, 12% growth. But the buffer is gone.
8 min
The Cannibalization Choice · Business Model
Novartis Spent a Decade Buying a $38 Billion Business — Then Gave It Away on Purpose
Over five years Novartis shed Alcon and Sandoz — $9.2 billion in annual generics revenue and a business it had paid roughly $38.5 billion to assemble. It wasn't a fire sale. It was a margin bet: every dollar of revenue it kept had to earn like a patent, not a commodity.
8 min
The Adjacency Expansion · Growth & Expansion
Novartis Paid $8.7 Billion to Cure a Disease Once. The Hard Part Is Doing It Twice.
Novartis bought the world's best-selling gene therapy for $8.7 billion. Then it discovered the trap: cure a one-shot disease and you exhaust your own market. Zolgensma peaked at $1.35 B in 2021 and has fallen ever since. The real test is whether the platform has a second act.
8 min
The Price Tag · Pricing
The $2 Million Drug Wasn't the Scandal. The Hidden Data Was.
Zolgensma's $2.125M price triggered outrage as 'the world's most expensive drug.' But the math was defensible — and an independent watchdog endorsed it. The real story is the manipulated data Novartis sat on, and the zero-penalty ending.
8 min